MONTY / PLAY
Listing on NASDAQ: everything you need to know with Pierluigi Paracchi, CEO of Genenta Science
AI illustrationThe player connects to YouTube only after your click and may share technical data with Google. This choice is separate from AskMonty analytics. How it works
If this video cannot play here, use the YouTube link.
BEFORE YOU PRESS PLAY
What is discussed
AskMonty AI editorial noteSource consulted:
Pierluigi Paracchi describes Genenta Science’s path to a Nasdaq listing, covering preparation, professional costs, fundraising and investor selection. He explains why building the investor book involves negotiation and why subsequent market trading does not itself bring new funds into the company. The interview also covers the listing ceremony and a period-specific update on the company’s experimental clinical research into cell therapies for cancer.
Key points
- Preparing the transaction requires organizational readiness, advisers and cost management while the outcome remains uncertain.
- Building the investor book balances capital raised, dilution and investor stability.
- Paracchi describes the ceremony’s promotional impact and presents Genenta’s clinical research as still experimental.
AI summary based on material from the linked source.
0glossary expressions documented here
Each expression counts once per item, even when repeated. The overall ranking covers the reviewed portion of the archive.
No documented matches for the checked variants in the available source material.
Checked against the source material. View source
